What is the recommended dose of Tamiflu (oseltamivir) for prophylaxis after exposure to someone with influenza?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Oseltamivir (Tamiflu) Prophylaxis Dosage After Influenza Exposure

For adults exposed to influenza, the recommended prophylactic dose of oseltamivir (Tamiflu) is 75 mg once daily for 10 days after exposure. 1

Adult Dosing

  • Standard adult dose: 75 mg once daily 2, 1
  • Duration: 10 days following close contact with an infected individual 1
  • Timing: Should be initiated within 48 hours of exposure for maximum effectiveness 2, 3
  • Renal impairment: For patients with creatinine clearance 10-30 mL/min, reduce dose to 30 mg once daily or 75 mg every other day 2, 3

Pediatric Dosing

Prophylactic dosing for children is weight-based:

Weight Prophylaxis Dosage Volume of Oral Suspension (6 mg/mL)
≤15 kg 30 mg once daily 5 mL
15.1-23 kg 45 mg once daily 7.5 mL
23.1-40 kg 60 mg once daily 10 mL
>40 kg 75 mg once daily 12.5 mL
  • Age requirement: Approved for prophylaxis in children ≥1 year of age 2, 1
  • Duration: 10 days following exposure 2, 1

Special Populations

  • Elderly patients: No dosage adjustment required based on age alone 2
  • Immunocompromised patients: May continue prophylaxis for up to 12 weeks 1
  • Institutional settings: Prophylaxis should continue until approximately 7-10 days after illness onset in the last patient during an outbreak 2

Important Considerations

  • Oseltamivir is not a substitute for influenza vaccination 1

  • Prophylaxis should be considered for:

    • Unvaccinated high-risk individuals 2, 3
    • During the 2 weeks after vaccination while immunity is developing 4
    • Unvaccinated family members and healthcare professionals with close contact to high-risk individuals 4
    • Control of influenza outbreaks in institutional settings 2
  • Taking oseltamivir with food may improve gastrointestinal tolerability 3

  • The effectiveness of prophylaxis lasts only as long as the medication is taken 1

Common Pitfalls to Avoid

  1. Delayed initiation: Starting prophylaxis beyond 48 hours after exposure significantly reduces effectiveness 3
  2. Incorrect dosing: Using treatment doses (twice daily) instead of prophylaxis doses (once daily) 1
  3. Inadequate duration: Not completing the full 10-day course 1
  4. Relying solely on prophylaxis: Viewing oseltamivir as a replacement for vaccination rather than as an adjunct 1, 5
  5. Overuse: Indiscriminate use may lead to viral resistance 5

Oseltamivir prophylaxis should be used judiciously as part of a comprehensive approach to influenza prevention, with vaccination remaining the primary preventive strategy when possible.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Influenza Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.